

## BÖLÜM 42

### PRİMER SANTRAL SİNİR SİSTEMİ LENFOMALARI

Ömer Faruk KUZU<sup>1</sup>

#### GENEL BİLGİLER

Primer santral sinir sistemi lenfomaları, tüm neoplazmların yaklaşık %3'ünü ve tüm ektranodal lenfomaların yaklaşık %4 ila %6'sını oluşturur.[1] Sistemik tutulum bulgusu olmaksızın beyin, göz omirilik, leptomeninkslerde gelişen Non-hodgkin lenfomaların agresiv formudur. Genel olarak immün sistemi normal olan kişiler arasında insidansı 1000 de 0.47'dir. Erkeklerde kadınlardan daha sık olmakla beraber yaş ile beraber sıklığı artmaktadır. [1] İmmünsüprese olmayan hastalarda AIDS ile ilişkili vakalara göre daha iyi bir prognoza sahiptir.[2] Primer diffüz büyük B-hücreli santral sinir sistemi lenfomaların %90'ı B-cell-like(ABC) alt tipin aktivasyonu ile gelişir[3]. Hastaların %90'nın da beyin parankimi tutulumu olmakla beraber bunların %50 si multifokaldir. %30 hastada diffüz yada parankime bitişik lokalize olabilen leptomenengial tutulum görülebilir. %10 ila %20 hastada bağımsız oküler tutulum izlenebilir. Multifokal tutulumdan ötürü ciddi semptomlar ile gelebilir.[4] İzole oküler tutulum ile gelen hastaların yarısında görme problemleri ile başvururlar. Direkt olarak göz içinde lenfoma gelişimi yada primer tümör gelişiminden birkaç hafta ya da birkaç ay sonrasında intraoküler tutulum gelişebilir.[5]

Hasta yönetiminde multidisipliner yaklaşım önemlidir.[6] Görüntüleme için kontrastlı MRI en iyi seçenektir. T2 ağırlıklı görüntülemelerde izodens/hipointens etrafı ödematöz homojen yapıda lezyon şeklindedir. Doğru bir evreleme hastalığı, hem hastalığın farklı santral sinir sisemi yapılarındaki yayılımını tanımlamayı hem de eşlik eden sistemik lenfomayı ekarte etmeyi amaçlar. F-18 FDG PET, kemik iliği biyopsisi/aspirasyonu ve testiküler ultrason %4-12 hasta arasında görülebilen ekstrakranial lenfomaların ekarte edilmesi ve evreleme için yapılmaktadır.[6] Son dönemlerde yeni kullanılmaya başlanan [68Ga]Ga-PentixaFor Pet görüntüleme yöntemi, C-X-C chemokine receptör4 (CXCR4)-positif maligniteler için hem görüntüleme hem de tedavi yanıtında kullanımının uygun olduğu göz-

<sup>1</sup> Uzm. Dr., Gülhane Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği drfarukkuzu@gmail.com

## KAYNAKLAR

1. Villano, J., et al., *Age, gender, and racial differences in incidence and survival in primary CNS lymphoma*. British journal of cancer, 2011. **105**(9): p. 1414-1418.
2. O'Neill, B.P., et al., *The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma*. American journal of hematology, 2013. **88**(12): p. 997-1000.
3. Batchelor, T.T., *Primary central nervous system lymphoma: A curable disease*. Hematological oncology, 2019. **37**: p. 15-18.
4. Bataille, B., et al., *Primary intracerebral malignant lymphoma: report of 248 cases*. Journal of neurosurgery, 2000. **92**(2): p. 261-266.
5. Ferreri, A., et al., *A multicenter study of treatment of primary CNS lymphoma*. Neurology, 2002. **58**(10): p. 1513-1520.
6. Calimeri, T., et al., *How we treat primary central nervous system lymphoma*. ESMO open, 2021. **6**(4): p. 100213.
7. Herhaus, P., et al., *CXCR4-targeted PET imaging of central nervous system B-cell lymphoma*. Journal of Nuclear Medicine, 2020. **61**(12): p. 1765-1771.
8. Abrey, L.E., et al., *Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma*. Journal of clinical oncology, 2005. **23**(22): p. 5034-5043.
9. Ferreri, A.J., et al., *Prognostic scoring system for primary CNS lymphomas: the International Extracranial Lymphoma Study Group experience*. Journal of Clinical Oncology, 2003. **21**(2): p. 266-272.
10. Abrey, L.E., et al., *Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model*. Journal of Clinical Oncology, 2006. **24**(36): p. 5711-5715.
11. Grommes, C. and L.M. DeAngelis, *Primary CNS lymphoma*. Journal of Clinical Oncology, 2017. **35**(21): p. 2410.
12. Batchelor, T., et al., *Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07*. Journal of Clinical Oncology, 2003. **21**(6): p. 1044-1049.
13. Bromberg, J.E., et al., *Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study*. The Lancet Oncology, 2019. **20**(2): p. 216-228.
14. Chamberlain, M.C. and S.K. Johnston, *High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma*. Neuro-oncology, 2010. **12**(7): p. 736-744.
15. DeAngelis, L.M., et al., *Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10*. Journal of Clinical Oncology, 2002. **20**(24): p. 4643-4648.
16. Gavrilocic, I.T., et al., *Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma*. Journal of Clinical Oncology, 2006. **24**(28): p. 4570-4574.
17. Shah, G.D., et al., *Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma*. Journal of Clinical Oncology, 2007. **25**(30): p. 4730-4735.
18. Wieduwilt, M.J., et al., *Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI Immunochemotherapy with Intensive Consolidation for PCNSL*. Clinical Cancer Research, 2012. **18**(4): p. 1146-1155.
19. Gregory, G., et al., *Rituximab is associated with improved survival for aggressive B cell CNS lymphoma*. Neuro-oncology, 2013. **15**(8): p. 1068-1073.
20. Holdhoff, M., et al., *High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma*. Neurology, 2014. **83**(3): p. 235-239.

21. Ly, K.I., et al., *Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience*. *Oncology Letters*, 2016. **11**(5): p. 3471-3476.
22. Omuro, A., et al., *R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma*. *Blood, The Journal of the American Society of Hematology*, 2015. **125**(9): p. 1403-1410.
23. Glass, J., et al., *Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG Oncology RTOG 0227*. *Journal of Clinical Oncology*, 2016. **34**(14): p. 1620.
24. Song, Y., et al., *Effect of rituximab on primary central nervous system lymphoma: a meta-analysis*. *International journal of hematology*, 2017. **106**(5): p. 612-621.
25. Ferreri, A.J., et al., *High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial*. *The Lancet*, 2009. **374**(9700): p. 1512-1520.
26. Schulz, H., et al., *Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab*. *Haematologica*, 2004. **89**(6): p. 753-754.
27. Abrey, L.E., et al., *Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis*. *Journal of clinical oncology*, 2003. **21**(22): p. 4151-4156.
28. Montemurro, M., et al., *Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hämato-Onkologie OSHO-53 phase II study*. *Annals of oncology*, 2007. **18**(4): p. 665-671.
29. Colombat, P., et al., *High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group*. *Bone marrow transplantation*, 2006. **38**(6): p. 417-420.
30. Illerhaus, G., et al., *High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system*. *Haematologica*, 2008. **93**(1): p. 147-148.
31. Cote, G.M., et al., *Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma*. *Biology of Blood and Marrow Transplantation*, 2012. **18**(1): p. 76-83.
32. Kasenda, B., et al., *Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study*. *Annals of oncology*, 2012. **23**(10): p. 2670-2675.
33. DeFilipp, Z., et al., *High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission*. *Cancer*, 2017. **123**(16): p. 3073-3079.
34. Ferreri, A.J., et al., *Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial*. *The Lancet Haematology*, 2017. **4**(11): p. e510-e523.
35. Widemann, B.C., et al., *Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome*. *Journal of clinical oncology*, 2010. **28**(25): p. 3979.
36. Widemann, B.C., et al., *High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma: incidence, treatment, and outcome*. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 2004. **100**(10): p. 2222-2232.
37. Abrey, L.E., J. Yahalom, and L.M. DeAngelis, *Treatment for primary CNS lymphoma: the next step*. *Journal of Clinical Oncology*, 2000. **18**(17): p. 3144-3150.
38. Bessell, E., et al., *Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treat-*

- ments. *Journal of Clinical Oncology*, 2002. **20**(1): p. 231-236.
39. Gerstner, E.R., et al., *Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation*. *Neurology*, 2008. **70**(5): p. 401-402.
  40. Hoang-Xuan, K., et al., *Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group*. *Journal of Clinical Oncology*, 2003. **21**(14): p. 2726-2731.
  41. Pels, H., et al., *Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy*. *Journal of Clinical Oncology*, 2003. **21**(24): p. 4489-4495.
  42. Illerhaus, G., et al., *High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study*. *Annals of oncology*, 2009. **20**(2): p. 319-325.
  43. Juergens, A., et al., *Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma*. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society*, 2010. **67**(2): p. 182-189.
  44. Illerhaus, G., et al., *High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial*. *The Lancet Haematology*, 2016. **3**(8): p. e388-e397.
  45. Omuro, A., et al., *Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANO-CEF-GOELAMS randomised phase 2 trial*. *The Lancet Haematology*, 2015. **2**(6): p. e251-e259.
  46. Fritsch, K., et al., *High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)*. *Leukemia*, 2017. **31**(4): p. 846-852.
  47. Morris, P.G., et al., *Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome*. *Journal of Clinical Oncology*, 2013. **31**(31): p. 3971.
  48. Pulczynski, E.J., et al., *Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group*. *haematologica*, 2015. **100**(4): p. 534.
  49. Jahnke, K., et al., *Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors*. *Journal of neuro-oncology*, 2006. **80**(2): p. 159-165.
  50. Holdhoff, M., N. Wagner-Johnston, and M. Roschewski, *Systemic approach to recurrent primary CNS lymphoma: perspective on current and emerging treatment strategies*. *OncoTargets and therapy*, 2020. **13**: p. 8323.
  51. Thiel, E., et al., *High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial*. *The lancet oncology*, 2010. **11**(11): p. 1036-1047.
  52. Grommes, C., et al., *Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma*. *Ibrutinib in Central Nervous System Lymphoma*. *Cancer discovery*, 2017. **7**(9): p. 1018-1029.
  53. Soussain, C., et al., *Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network*. *European journal of cancer*, 2019. **117**: p. 121-130.
  54. Rubenstein, J.L., et al., *Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma*. *Blood advances*, 2018. **2**(13): p. 1595-1607.
  55. Tun, H.W., et al., *Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma*. *Blood, The Journal of the American Society of Hematology*, 2018. **132**(21): p. 2240-2248.